Affinage

CHD5

Guided entry of tail-anchored proteins factor 1 · UniProt O00258

Length
174 aa
Mass
19.8 kDa
Annotated
2026-06-09
59 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CHD5 is an ATP-dependent chromatin-remodeling ATPase that functions as a tumor suppressor and a master regulator of cell-fate transitions in the nervous system and germline (PMID:17289567, PMID:23318260). Biochemically, CHD5 is a nucleosome-stimulated ATPase that remodels nucleosomes by exposing nucleosomal DNA (unwrapping) in an ATP-hydrolysis-dependent manner, an activity distinct from the nucleosome-repositioning enzymes ACF and BRG1 and more efficient at unwrapping than its paralog CHD4 (PMID:24923445, PMID:24849318). Its tandem PHD fingers read the unmodified N-terminus of histone H3, engaging two H3 tails simultaneously with enhanced affinity, while modifications at H3R2, H3K4, H3T3, H3T6, and H3S10 abolish binding (PMID:22834704). CHD5 assembles into a megadalton NuRD-type repressor complex containing HDAC1/2, MTA1/2, GATAD2A, RBBP4/7, and MBD2/3, and its incorporation appears mutually exclusive with CHD4 (PMID:21931736, PMID:25825869, PMID:25247294). Chromatin engagement is essential for function: PHD mutations that abolish H3 binding eliminate CHD5's ability to inhibit proliferation, modulate target genes, and suppress tumors, and a catalytically inactive mutant still joins NuRD but fails to repress transcription (PMID:23318260, PMID:25247294). Through direct promoter binding, CHD5 represses the G2/M regulator WEE1 and a broad oncogenic program (MYC, MDM2, STAT3, CCND1, YAP1, EZH2, Bmi-1) while controlling proliferation, apoptosis, and senescence via the p19Arf/p53 pathway (PMID:25247294, PMID:26943038, PMID:17289567); its tumor-suppressor output extends to metastasis through a CHD5→PLCL1/p53 axis (PMID:34789839). In the developing brain CHD5 drives neuronal differentiation, in part via a Chd5→Six3→Wnt5a transcriptional cascade (PMID:36636025), and in the male germline it orchestrates the histone-to-protamine transition required for sperm chromatin condensation (PMID:24252660, PMID:24818823). CHD5 is itself silenced in cancer by promoter CpG hypermethylation, PRC2-mediated H3K27me3, and post-transcriptional repression by miR-211 (PMID:18698156, PMID:26517514, PMID:22235338).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2007 High

    Established CHD5 as a genuine tumor suppressor acting through a defined pathway, answering whether the 1p36 candidate gene had causal anti-tumor activity in vivo.

    Evidence Chromosome engineering of mouse gain/loss models with p19Arf/p53 pathway epistasis

    PMID:17289567

    Open questions at the time
    • Did not define the molecular/enzymatic activity of CHD5
    • Direct gene targets not yet identified
  2. 2008 Medium

    Explained how CHD5 is inactivated in human tumors without mutation, showing promoter CpG hypermethylation uniquely silences CHD5 among CHD family members.

    Evidence Methylation profiling of CHD1-9 in cancer lines/primary tumors with 5-aza demethylation rescue

    PMID:18698156

    Open questions at the time
    • Correlative across tumor types
    • Did not address downstream consequences of silencing on specific targets
  3. 2011 Medium

    Provided the first biochemical picture of CHD5 as a NuRD-like complex member that binds neuronal gene promoters, linking it to transcriptional repression in neurons.

    Evidence Co-IP, ChIP, expression profiling and fractionation from mouse brain

    PMID:21931736

    Open questions at the time
    • Partial complex composition only
    • No catalytic or remodeling mechanism defined
  4. 2012 High

    Defined the histone reader specificity of CHD5, showing tandem PHD fingers recognize unmodified H3 N-termini and engage two tails cooperatively.

    Evidence Peptide arrays, NMR, SPR and quantitative binding assays

    PMID:22834704

    Open questions at the time
    • In vitro peptide system, not nucleosomal context
    • Did not link binding to in vivo function
  5. 2012 Medium

    Identified upstream regulators of CHD5, placing it under control of JMJD2A/KDM4A and miR-211 to connect CHD5 loss to the p53 pathway and tumor growth.

    Evidence JMJD2A gain/loss with Ras cooperation assays; miR-211 3'-UTR luciferase reporter and xenograft assays

    PMID:22235338 PMID:23168260

    Open questions at the time
    • Regulatory effects on CHD5 are indirect/post-transcriptional
    • p53 pathway effects inferred from downstream proteins
  6. 2013 High

    Proved that chromatin binding is mechanistically required for tumor suppression by linking PHD-mediated H3 reading to all functional outputs.

    Evidence PHD mutagenesis, genome-wide ChIP-seq, xenograft and neuroblastoma differentiation assays

    PMID:23318260

    Open questions at the time
    • Did not resolve the remodeling enzymology
    • Full target gene network only partially defined
  7. 2013 Low

    Began to dissect transcriptional control of CHD5 itself, showing AP2 activates the CHD5 promoter in a methylation-sensitive manner.

    Evidence ChIP-PCR, luciferase reporter, AP2 overexpression, DAC treatment

    PMID:24454811

    Open questions at the time
    • Limited mechanistic dissection, ChIP and reporter only
    • No in vivo validation
  8. 2014 High

    Resolved the enzymatic mechanism, defining CHD5 as a nucleosome-stimulated ATPase that unwraps rather than repositions nucleosomes, distinguishing it from ACF, BRG1, and CHD4.

    Evidence In vitro nucleosome remodeling and ATPase assays with comparison to related ATPases; recombinant zebrafish protein assays

    PMID:24849318 PMID:24923445 PMID:26092436

    Open questions at the time
    • Structural basis of unwrapping not determined
    • Physiological consequences of unwrapping vs repositioning unclear
  9. 2014 High

    Completed the NuRD complex membership map and tied catalytic activity to repression, showing CHD5/NuRD represses WEE1 and that catalytic activity (not complex assembly) is required for repression.

    Evidence Endogenous complex purification, reciprocal Co-IP, GST-FOG1 pulldown, MS/MS, catalytically inactive mutant analysis

    PMID:25247294 PMID:25825869

    Open questions at the time
    • Mechanism of CHD5/CHD4 mutual exclusivity unresolved
    • Full target gene repertoire not exhaustively defined
  10. 2014 High

    Established a germline function, showing CHD5 is required for the histone-to-protamine transition and sperm chromatin condensation.

    Evidence Chd5 knockout mice with histology, EM, histone-modification immunofluorescence and gene expression of transition proteins/protamines

    PMID:24252660 PMID:24818823 PMID:24849318

    Open questions at the time
    • Direct chromatin targets in spermatids not mapped
    • Mechanistic link from H4 hyperacetylation to nucleosome eviction incomplete
  11. 2014 Medium

    Connected CHD5 expression to neuronal differentiation programs and placed it downstream of retinoic acid and NGF/TrkA signaling.

    Evidence Developmental immunostaining in mouse brain; 13cRA and TrkA induction with pan-TRK blockade in neuroblastoma lines

    PMID:24120991 PMID:26245651

    Open questions at the time
    • Cause of cytoplasm-to-nucleus localization switch unknown
    • Mechanism linking TrkA signaling to CHD5 induction undefined
  12. 2015 Medium

    Broadened CHD5's repressive target spectrum and revealed reciprocal antagonism with PRC2/EZH2 and silencing by H3K27me3.

    Evidence ChIP, luciferase reporters and gain-of-function expression in RCC and HCC cells; CRISPR KO mESC analysis of MERVL/H3K27me3

    PMID:26359639 PMID:26517514 PMID:26943038

    Open questions at the time
    • Single-lineage observations not generalized
    • Direct vs indirect repression of each target not fully separated
  13. 2021 Medium

    Extended tumor suppression beyond proliferation to metastasis, identifying a CHD5→PLCL1/p53 effector axis.

    Evidence Forced expression in neuroblastoma, RNA-seq, in vivo metastasis model, PLCL1/p53 knockdown epistasis

    PMID:34789839

    Open questions at the time
    • Whether PLCL1 is a direct CHD5 target not established
    • Mechanism of p53 cooperation in metastasis unresolved
  14. 2023 Medium

    Defined a transcriptional hierarchy for CHD5 in neurogenesis, establishing the Chd5→Six3→Wnt5a axis for neuronal lineage specification.

    Evidence Transcriptional profiling and genetic epistasis in Chd5 knockout mouse cells across differentiation stages

    PMID:36636025

    Open questions at the time
    • Whether Six3 is a direct chromatin target of CHD5 not shown
    • NuRD requirement for this axis not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CHD5's nucleosome-unwrapping activity, PHD-mediated H3 reading, and NuRD assembly are integrated into target-gene selection across distinct tissues remains undefined.
  • No structural model of CHD5 on a nucleosome
  • Determinants of tissue-specific target selection unknown
  • Basis for CHD5 vs CHD4 NuRD partitioning unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 3 GO:0140657 ATP-dependent activity 3 GO:0016787 hydrolase activity 2 GO:0042393 histone binding 2
Localization
GO:0005634 nucleus 2 GO:0005694 chromosome 1
Pathway
R-HSA-1643685 Disease 3 R-HSA-4839726 Chromatin organization 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1266738 Developmental Biology 2 R-HSA-1474165 Reproduction 2
Partners
GATAD2AHDAC1HDAC2MBD2MBD3MTA1MTA2RBBP4
Complex memberships
NuRD complex

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 Chd5 functions as a tumor suppressor that controls proliferation, apoptosis, and senescence via the p19(Arf)/p53 pathway, as demonstrated by chromosome engineering to generate mouse models with gain and loss of the 1p36-corresponding region. Chromosome engineering (mouse models), in vivo tumor suppression assays, genetic epistasis with p19Arf/p53 pathway Cell High 17289567
2011 CHD5 protein isolated from mouse brain is associated with HDAC2, p66β, MTA3, and RbAp46 in a megadalton NuRD-like complex; CHD5 is predominantly nuclear in neurons and directly binds target neuronal gene promoters as shown by chromatin immunoprecipitation. Co-immunoprecipitation, microarray expression profiling after CHD5 depletion, chromatin immunoprecipitation (ChIP), subcellular fractionation/immunostaining PloS one Medium 21931736
2012 The tandem PHD fingers of CHD5 specifically recognize the unmodified N-terminus of histone H3; modifications at H3R2, H3K4, H3T3, H3T6, and H3S10 disrupt binding, and the tandem PHD1-2 simultaneously engages two H3 N-termini with 4-11-fold increased affinity compared to individual PHD fingers. Modified peptide-library platforms (bead and glass slide), NMR, surface plasmon resonance, biochemical binding assays Biochemistry High 22834704
2013 Chd5 binds the unmodified N-terminus of histone H3 through its tandem PHD domains; PHD mutations that abrogate H3 binding abolish Chd5's ability to inhibit proliferation, transcriptionally modulate target genes, and suppress tumor growth in vivo, establishing that chromatin binding is required for tumor suppression. PHD domain mutagenesis, genome-wide ChIP-seq, in vivo xenograft tumor assays, neuroblastoma differentiation assays Cell reports High 23318260
2013 Chd5 knockout male mice display defective spermiogenesis with impaired chromatin condensation, abnormal sperm head morphology, and decreased H4 hyperacetylation at stage IX, establishing CHD5 as required for the histone-to-protamine transition during spermatogenesis. Knockout mouse model, histology, electron microscopy, acidic aniline staining, immunofluorescence for histone modifications Mechanisms of development High 24252660
2014 CHD5 is a component of the full NuRD transcriptional repressor complex (containing methyl-CpG binding proteins and HDACs); overexpression of CHD5 results in loss of CHD4 protein, suggesting the CHD5/NuRD and CHD4/NuRD complexes are mutually exclusive. CHD5 binds and represses the G2/M checkpoint gene WEE1, and a catalytically inactive CHD5 mutant associates with NuRD but fails to repress transcription. Biochemical purification of human CHD5 complex, co-immunoprecipitation, CHD5 re-introduction into neuroblastoma cells, catalytically inactive mutant analysis, gene expression assays PloS one High 25247294
2014 CHD5 is a chromatin remodeling ATPase that exposes nucleosomal DNA at discrete positions (nucleosome unwrapping) in an ATP hydrolysis-dependent manner; continued ATP hydrolysis is not required to maintain the remodeled state, and this activity is distinct from ACF and BRG1, which reposition nucleosomes. CHD4 shows strong ATPase activity but does not unwrap nucleosomes as efficiently as CHD5. In vitro nucleosome remodeling assay, ATPase assay, comparison with related remodeling ATPases The Journal of biological chemistry High 24923445
2014 Chd5 orchestrates a cascade of molecular events during spermiogenesis required for histone removal and replacement: H4 hyperacetylation, histone variant expression, nucleosome eviction, DNA damage repair, and expression of transition proteins (Tnp1/Tnp2) and protamines (Prm1/2). Chd5 deficiency leads to defective sperm chromatin compaction and male infertility. Chd5 knockout mouse, spermiogenesis phenotyping, molecular analysis of histone modifications, gene expression (mRNA), chromatin compaction assays Nature communications High 24818823
2014 CHD5 is expressed during neuronal differentiation in the developing mouse brain; Chd5 subcellular localization switches from cytoplasm to nucleus during mid-gestation, and high nuclear levels are maintained in differentiated adult neurons. Immunostaining of endogenous Chd5 protein across developmental time points in mouse brain sections, subcellular localization analysis Gene expression patterns : GEP Medium 24120991
2014 CHD5 is a nucleosome-stimulated ATPase (demonstrated with recombinant zebrafish Chd5 protein in vitro); knockdown of Chd5 during zebrafish embryogenesis causes craniofacial development defects and impaired dopaminergic amacrine cell differentiation, establishing a conserved role in neuronal differentiation. In vitro nucleosome remodeling/ATPase assay with recombinant protein, morpholino knockdown in zebrafish, neural marker expression analysis Biochimica et biophysica acta Medium 26092436
2014 CHD5 is clearly associated with all canonical NuRD components—MTA1/2, GATAD2A, HDAC1/2, RBBP4/7, and MBD2/3—as determined by immunoprecipitation from neuroblastoma cell nuclear extracts and confirmed by MS/MS analysis. GST-FOG1 pulldown also identified NuRD components associated with CHD5. Co-immunoprecipitation from endogenous and V5-tagged CHD5 cells, GST-FOG1 pulldown, MS/MS mass spectrometry, Western blotting The Biochemical journal High 25825869
2015 Chd5 represses murine endogenous retrovirus-L (MuERV-L/MERVL) retrotransposons in mouse embryonic stem cells by regulating H3K27me3 modification and histone H3.1/H3.2 incorporation. CRISPR-Cas9 knockout of Chd5 locus in mESCs, analysis of MERVL expression, ChIP for H3K27me3, histone variant analysis Journal of cellular biochemistry Medium 26359639
2014 CHD5 expression in spermatogenesis is restricted to post-meiotic round spermatids with a maximum at stage VIII, shows complementary expression with CHD3/4, and CHD5 co-localizes with macroH2A1.2 at centromeres and part of the Y chromosome in post-meiotic cells, suggesting a role in sex chromosome chromatin regulation. CHD5 was demonstrated to be a nucleosome-stimulated ATPase in vitro. Immunostaining of mouse testis sections across spermatogenic stages, co-localization with macroH2A1.2, in vitro ATPase assay PloS one Medium 24849318
2012 The lysine demethylase JMJD2A/KDM4A transcriptionally represses CHD5, blocking Ras-induced upregulation of CHD5 and thereby reducing p53 pathway activity to promote cellular transformation. Gene expression analysis after JMJD2A overexpression/depletion, oncogenic Ras cooperation assays, cellular senescence assays, p53 pathway reporter assays Cell reports Medium 23168260
2012 miR-211 directly binds the 3'-UTR of CHD5 mRNA, causing ~50% reduction in CHD5 protein level and promoting colorectal cancer cell proliferation, migration, and tumor growth; enforced miR-211 expression alters p53 pathway proteins (MDM2, Bcl-2, Bcl-xL, Bax). Lentiviral miR-211 overexpression, luciferase 3'-UTR reporter assay, Western blot, xenograft tumor assay, flow cytometry PloS one Medium 22235338
2016 CHD5 acts as a transcriptional repressor of multiple oncogenes (MYC, MDM2, STAT3, CCND1, YAP1), epigenetic master genes (Bmi-1, EZH2, JMJD2C), and EMT/stem cell markers (SNAI1, FN1, OCT4) in renal cell carcinoma cells; ChIP assays confirmed direct CHD5 binding to target gene promoters. Ectopic CHD5 expression in RCC cells, qRT-PCR, Western blot, chromatin immunoprecipitation (ChIP), clonogenicity/migration/invasion assays Oncotarget Medium 26943038
2015 CHD5 and EZH2 mutually repress each other's transcription: CHD5 is epigenetically silenced by PRC2-mediated H3K27me3 in HCC cells, and overexpression of CHD5 in turn represses EZH2 and activates PRC2 target genes p16 and p21. ChIP and luciferase reporter assays confirmed reciprocal promoter binding. ChIP for H3K27me3, ChIP for CHD5 and EZH2 binding to respective promoters, luciferase reporter assays, gain-of-function CHD5 expression Oncotarget Medium 26517514
2015 CHD5 upregulation is induced by retinoic acid (13cRA) treatment in a time- and dose-dependent manner only in neuroblastoma cell lines that subsequently undergo neuronal differentiation; NGF/TrkA signaling also induces CHD5 upregulation and differentiation, placing CHD5 downstream of TrkA signaling. 13cRA treatment of NB cell lines, qRT-PCR, Western blot, pan-TRK inhibitor blockade, TrkA transfection experiments, morphological differentiation assessment Molecular cancer Medium 26245651
2021 CHD5 forced expression in neuroblastoma cells with 1p loss inhibits anchorage-independent growth, migration, and invasion in vitro, and delays/reduces bone marrow and liver metastasis in vivo. Genome-wide mRNA sequencing revealed upregulation of the metastasis suppressor PLCL1; knockdown of PLCL1 or p53 reversed CHD5-induced inhibition of invasion, placing PLCL1 and p53 as downstream effectors of CHD5 metastasis suppression. Forced CHD5 expression in NB cell lines, in vitro migration/invasion/anchorage-independent growth assays, intravenous xenograft mouse model, genome-wide RNA-seq, PLCL1 and p53 knockdown epistasis experiments Oncogene Medium 34789839
2023 Chd5 promotes neuronal differentiation by directing stepwise transcriptional changes: during early neurogenesis, Chd5 promotes expression of the proneural transcription factor Six3, which in turn represses Wnt5a (a non-canonical Wnt ligand required for neuronal maturation), establishing a Chd5→Six3→Wnt5a regulatory axis critical for lineage specification. Transcriptional profiling of Chd5-deficient mouse cells at early and late neuronal differentiation stages, genetic epistasis using Chd5 knockout mouse model Stem cells (Dayton, Ohio) Medium 36636025
2008 CHD5 promoter CpG island hypermethylation silences CHD5 expression in cancer; CHD5 is the only CHD family member (CHD1-9) whose promoter is hypermethylated in human cancer cell lines and primary tumors (gliomas, colon, breast carcinomas). Treatment with DNA demethylating agent restores CHD5 mRNA expression. Methylation profiling of CHD family members in cancer lines and primary tumors, RT-qPCR, 5-aza-2'-deoxycytidine demethylation treatment Epigenetics Medium 18698156
2013 The transcription factor AP2 activates CHD5 promoter activity; CHD5 promoter methylation represses AP2 recruitment and reduces promoter activity. Treatment with DNA methyltransferase inhibitor DAC increases AP2 recruitment to the CHD5 promoter. Chromatin immunoprecipitation (ChIP-PCR), luciferase reporter assay, AP2 overexpression, DAC treatment PloS one Low 24454811

Source papers

Stage 0 corpus · 59 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 CHD5 is a tumor suppressor at human 1p36. Cell 282 17289567
2008 CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. Journal of the National Cancer Institute 145 18577749
2003 CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 140 12592387
2012 JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell reports 100 23168260
2012 MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PloS one 96 22235338
2014 Chd5 orchestrates chromatin remodelling during sperm development. Nature communications 93 24818823
2011 CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PloS one 80 21931736
2014 Role of CHD5 in human cancers: 10 years later. Cancer research 75 24419087
2013 CHD5 is required for spermiogenesis and chromatin condensation. Mechanisms of development 69 24252660
2008 Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 67 18698156
2009 CHD5 is down-regulated through promoter hypermethylation in gastric cancer. Journal of biomedical science 60 19840376
2015 miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma. Oncotarget 52 26287602
2010 Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Molecular cancer 52 20950435
2012 Mechanisms of CHD5 Inactivation in neuroblastomas. Clinical cancer research : an official journal of the American Association for Cancer Research 48 22294723
2011 CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung cancer (Amsterdam, Netherlands) 48 22186629
2013 Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer 44 24243398
2013 Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Cell reports 41 23318260
2011 The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. Oral oncology 41 21636313
2015 The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex. The Biochemical journal 39 25825869
2012 Multivalent recognition of histone tails by the PHD fingers of CHD5. Biochemistry 39 22834704
2012 Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo. International journal of molecular medicine 37 22960751
2017 Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5. International journal of molecular medicine 35 29115379
2021 Missense and truncating variants in CHD5 in a dominant neurodevelopmental disorder with intellectual disability, behavioral disturbances, and epilepsy. Human genetics 29 33944996
2015 Chd5 Regulates MuERV-L/MERVL Expression in Mouse Embryonic Stem Cells Via H3K27me3 Modification and Histone H3.1/H3.2. Journal of cellular biochemistry 27 26359639
2016 The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. Oncotarget 25 26943038
2014 The chromatin remodeling factor CHD5 is a transcriptional repressor of WEE1. PloS one 24 25247294
2015 Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma. Molecular cancer 23 26245651
2011 Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. The British journal of dermatology 23 21250965
2016 miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5. Future oncology (London, England) 22 27513190
2014 The tumor suppressor chromodomain helicase DNA-binding protein 5 (CHD5) remodels nucleosomes by unwrapping. The Journal of biological chemistry 22 24923445
2020 SLC16A1-AS1 enhances radiosensitivity and represses cell proliferation and invasion by regulating the miR-301b-3p/CHD5 axis in hepatocellular carcinoma. Environmental science and pollution research international 20 32748357
2015 Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma. Oncotarget 20 26517514
2021 CHD5 inhibits metastasis of neuroblastoma. Oncogene 19 34789839
2016 Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas. Oncotarget 18 26895110
2013 The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain. Gene expression patterns : GEP 18 24120991
2005 Cooperative function of the CHD5-like protein Mdm39p with a P-type ATPase Spf1p in the maintenance of ER homeostasis in Saccharomyces cerevisiae. Molecular genetics and genomics : MGG 17 15909163
2014 CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver 16 24529164
2014 Differential expression and sex chromosome association of CHD3/4 and CHD5 during spermatogenesis. PloS one 16 24849318
2017 CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC). Gene 13 28400267
2014 Silencing of CHD5 gene by promoter methylation in leukemia. PloS one 13 24454811
2019 rs187960998 polymorphism in miR-211 prevents development of human colon cancer by deregulation of 3'UTR in CHD5. OncoTargets and therapy 11 30655677
2022 Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma. International journal of molecular sciences 10 35955624
2019 Clinical significance of chromatin remodeling factor CHD5 expression in gastric cancer. Oncology letters 10 31897220
2016 Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation. Oncology letters 9 27895765
2015 The chromatin remodeler chd5 is necessary for proper head development during embryogenesis of Danio rerio. Biochimica et biophysica acta 9 26092436
2008 Mutation screening of CHD5 in melanoma-prone families linked to 1p36 revealed no deleterious coding or splice site changes. BMC research notes 9 18803848
2021 CircRtn4 Acts as the Sponge of miR-24-3p to Promote Neurite Growth by Regulating CHD5. Frontiers in molecular neuroscience 8 34305525
2023 Chd5 Regulates the Transcription Factor Six3 to Promote Neuronal Differentiation. Stem cells (Dayton, Ohio) 7 36636025
2018 A rare CHD5 haplotype and its interactions with environmental factors predicting hepatocellular carcinoma risk. BMC cancer 7 29907144
2020 [Epigallocatechin gallate induces CHD5 gene demethylation to promote acute myeloid leukemia cell apoptosis in vitro by regulating p19Arf-p53-p21Cip1 signaling pathway]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 6 32990229
2010 A rat monoclonal antibody against the chromatin remodeling factor CHD5. Hybridoma (2005) 6 20199154
2022 CHD5 gene (rs9434741) might be a genetic risk factor for infertility in non-obstructive azoospermia and severe oligozoospermia. Andrologia 5 36102082
2023 CHD5 gene variant predicts leptomeningeal metastasis after surgical resection of brain metastases of breast cancer. Journal of neuro-oncology 3 37440096
2021 Overexpression of chromodomain helicase DNA binding protein 5 (CHD5) inhibits cell proliferation and induces cell cycle arrest and apoptosis in chronic myeloid leukemia. Translational cancer research 3 35116408
2019 [Methylation of CHD5 Gene Promoter Regulates p19Arf/p53/p21Cip1 Pathway to Facilitate Pathogenesis of Acute Myeloid Leukemia]. Zhongguo shi yan xue ye xue za zhi 3 31418348
2015 Influence of colorectal cancer tumor suppressor gene CHD5 methylation on its clinical and pathological characteristics. Journal of biological regulators and homeostatic agents 2 26753653
2025 Cell death pathway regulation by fatty acid metabolism-related genes in neuroblastoma: a multi-omics analysis identifying CHD5 as a novel biomarker. Discover oncology 1 40121577
2025 New Insights into the Relation between Cognition, Behavior, and the CHD5 Gene: A Case-Report of an Adult Male with Parenti-Mignot Neurodevelopmental Syndrome. Molecular syndromology 0 41584030
2024 Evaluation of CHD5, H3K9me3, and H4K12ac in Human Testes with Spermatogenic Maturation Arrest: A Cross-Sectional Study. International journal of fertility & sterility 0 38973279

Missed literature

Know a paper Affinage missed for CHD5? Flag it for the maintainers and the community.

No submissions yet.